Immunoassay Development
TGA Sciences, Inc. capabilities include:
TGA Sciences, Inc. offers our clients a complete package of development, optimization and quantification systems utilized in pre-clinical through Phase IV studies, all in compliance with GLP and cGMP requirements. We have a strong track record of expertise in the development of complex and infrequently used methods to assist our clients in their research. We offer weekly progress reports and/or teleconferences to ensure the client is up to date on all aspects of their projects. Capabilities include:
-
Measurement of small molecules, peptides and large proteins for R&D or product release (cGMP)
-
Immunoassays for the monitoring of antibody or protein levels throughout a clinical study in complete compliance with GLP guidelines
-
Development of an Immunoassay-based screening protocol against your lead compound
-
Assay design and detection systems for antibodies with unique specifications; Quantitative detection systems for antibodies with unique specifications
-
Quantitative detection systems for the determination of contaminants in highly purified products
-
Immunoassays utilized for the detection of cytokines or cell surface markers
-
Use of commercial kits in compliance with cGMP or GLP guidelines
-
Monoclonal antibody screening (Western blot or ELISA)
Immunoassay formats include:
-
Bridging Assay
-
Competitive Technique
-
Direct Binding Assay Study
-
HACA
-
HAMA
-
Immunogenicity Assays
-
immunoglobulin Screening
-
Isotyping
-
Client Specific Assay Formats